Diana Do, MD

  The FDA approved Encelto, an encapsulated cell therapy, for the treatment of macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

Macular telangiectasia type 2 is a progressive and relatively rare neurodegenerative disease of the macula that typically affects patients who are older than 40 years of age, more predominantly women.

CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Diana Do, MD, discusses the PHOTON extension study, which examined the effect of Eylea HD in patients with diabetic macular edema.

In this Healio Video Perspective from the ASRS meeting, Diana V. Do, MD, FASRS, of Byers Eye Institute discusses data from the PHOTON trial investigating aflibercept 8 mg and aflibercept 2 mg for the treatment of diabetic macular edema.

In this Healio Video Perspective from the AAO meeting, Diana V. Do, MD, overviews positive 96-week efficacy and safety data from the PHOTON study investigating aflibercept 8 mg in patients with diabetic macular edema.

In this video, Diana Do, MD, Professor of Ophthalmology at the Stanford University School of Medicine, discusses the promising early results shown by the implementation of faricimab into diabetic macular edema treatment plans.

In this video, Diana Do, MD, Professor of Ophthalmology at the Stanford University School of Medicine, discusses how she puts together a treatment plan for diabetic macular edema, and how she implements a personalized, individualized approach for each patient.

In this video, Diana Do, MD, Professor of Ophthalmology at the Stanford University School of Medicine, discusses the importance of vision education for patients of diabetic macular edema, and important factors in reducing serious symptoms.

In this video, Diana Do, MD, Professor of Ophthalmology at the Stanford University School of Medicine, discusses major unmet needs in the treatment of diabetic macular edema, especially the need for greater disease control in longer treatment intervals.

In this video, Diana Do, MD, Professor of Ophthalmology at the Stanford University School of Medicine, discusses the 'bright future' for DME treatment with new drugs coming down the pipeline.